Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.45 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.43 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.43 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.41 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | DHODH | Q02127 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20552799 | 0.88 | SLC22A12 (0.47) | SLC22A12KIF11TEAD1TEAD4TEAD2 | |
| SCHEMBL20552318 | 0.84 | LRRK2 (0.50) | KIF11TEAD1TEAD4TEAD2MPO | |
| SCHEMBL20552788 | 0.82 | LRRK2 (0.49) | KIF11TEAD1TEAD4TEAD2MAPT | |
| SCHEMBL20552520 | 0.82 | KIF11 (0.45) | KIF11TEAD1TEAD4TEAD2MAPT | |
| SCHEMBL20767101 | 0.82 | KIF11 (0.45) | KIF11TEAD1TEAD4TEAD2MAPT | |
| SCHEMBL30410880 | 0.82 | KIF11 (0.45) | KIF11TEAD1TEAD4TEAD2MAPT | |
| SCHEMBL4193660 | 0.80 | GAA (0.54) | SLC22A12MAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL20552334 | 0.79 | TRPV1 (0.44) | KIF11TEAD1TEAD4TEAD2MAPT | |
| SCHEMBL20553063 | 0.79 | LRRK2 (0.52) | KIF11TEAD1TEAD4TEAD2DHODH | |
| SCHEMBL20553187 | 0.78 | TEAD1 (0.53) | SLC22A12KIF11TEAD1TEAD4TEAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186554-B2 | Non-fused tricyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186554-B2 | Non-fused tricyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| CN-111132673-A | Non-fused tricyclic compounds | 维瓦斯治疗公司 | 2020-05-08 | — | — | CN | disclosed |
| EP-3618818-A1 | NON-FUSED TRICYCLIC COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2020-03-11 | — | — | EP | disclosed |
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
| WO-2018204532-A1 | NON-FUSED TRICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2018-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | YAP1, MYC, TEAD2 | SLC22A12 4433/4885KIF11 2182/4885TEAD1 8/4885 |
| US-11186554-B2 | Non-fused tricyclic compounds | YAP1, MYC, TEAD2 | SLC22A12 4433/4885KIF11 2182/4885TEAD1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.